Novartis AG (NYSE:NVS) Holdings Boosted by Foresight Capital Management Advisors Inc.

Foresight Capital Management Advisors Inc. boosted its holdings in Novartis AG (NYSE:NVS) by 7.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 24,604 shares of the company’s stock after acquiring an additional 1,729 shares during the period. Foresight Capital Management Advisors Inc.’s holdings in Novartis were worth $2,394,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Integral Health Asset Management LLC raised its holdings in shares of Novartis by 33.3% during the second quarter. Integral Health Asset Management LLC now owns 300,000 shares of the company’s stock valued at $31,938,000 after buying an additional 75,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Novartis by 115.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock worth $26,797,000 after purchasing an additional 124,111 shares in the last quarter. Bank of Montreal Can raised its holdings in Novartis by 343.5% during the second quarter. Bank of Montreal Can now owns 657,903 shares of the company’s stock worth $70,652,000 after purchasing an additional 509,567 shares in the last quarter. CWA Asset Management Group LLC raised its holdings in Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock worth $3,001,000 after purchasing an additional 5,164 shares in the last quarter. Finally, Quantbot Technologies LP raised its holdings in Novartis by 135.5% during the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after purchasing an additional 22,998 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Erste Group Bank reissued a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. BMO Capital Markets lifted their price objective on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Finally, HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $121.50.

Novartis Trading Down 0.3 %

Novartis stock opened at $99.05 on Thursday. The company’s fifty day simple moving average is $101.13 and its 200-day simple moving average is $109.19. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The stock has a market cap of $202.46 billion, a P/E ratio of 11.50, a P/E/G ratio of 1.36 and a beta of 0.57.

Novartis (NYSE:NVS) last released its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same quarter in the previous year, the business earned $1.74 EPS. As a group, sell-side analysts forecast that Novartis AG will post 7.63 EPS for the current fiscal year.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.